Hepatic Encephalopathy

Clinics in Liver Disease

Volumn 16, Issue 2, 2012, Pages 301-320

  Khungar, Vandana ^a,b   Poordad, Fred ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatic encephalopathy; Minimal hepatic encephalopathy; Overt hepatic encephalopathy; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACARBOSE; ACETYLCHOLINESTERASE; AMMONIA; AST 120; ENDOTOXIN; GLUTAMINASE; IMMUNOGLOBULIN G; INOSITOL; INTERLEUKIN 1; INTERLEUKIN 6; LACTITOL; LACTULOSE; NEOMYCIN; PENTOXIFYLLINE; POTASSIUM; PROBIOTIC AGENT; PROTHROMBIN; RIFAXIMIN; SERUM ALBUMIN; SYNBIOTIC AGENT; TESTOSTERONE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACID BASE BALANCE; ACIDOSIS; ADVANCED CANCER; ALBUMIN BLOOD LEVEL; ALKALOSIS; AMMONIA FORMATION; ASTROCYTOSIS; BACTERIAL OVERGROWTH; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; BLOATING; BRAIN EDEMA; CAREGIVER BURDEN; CATABOLISM; CHRONIC LIVER DISEASE; COGNITION; COGNITIVE DEFECT; COMA; CYTOKINE PRODUCTION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE TITRATION; END STAGE LIVER DISEASE; ENDOTOXEMIA; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; HYPERAMMONEMIA; HYPERNATREMIA; HYPOKALEMIA; HYPONATREMIA; INTESTINE FLORA; KIDNEY FAILURE; LIVER CIRRHOSIS; MENTAL HEALTH; META ANALYSIS (TOPIC); METABOLIC ENCEPHALOPATHY; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; MULTICENTER STUDY (TOPIC); MUSCLE ATROPHY; MUSCLE CELL; NAUSEA AND VOMITING; NEUROMODULATION; NEUROTRANSMISSION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PH; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PROTEIN RESTRICTION; PROTON TRANSPORT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE TIME; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SURVIVAL RATE; TESTOSTERONE BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; WORKING MEMORY;

AMMONIA; ANTI-BACTERIAL AGENTS; ANTIDOTES; CHARCOAL; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LACTULOSE; PREBIOTICS; PROBIOTICS; RIFAMYCINS;

EID: 84860280208     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.03.009     Document Type: Review

References (118)

1. Voight M, Conn H. Hepatic encephalopathy. In: Robson SC, Trey C, Kirsch RE (editors). Diagnosis and management of liver disease. Chapman & Hall, London, p. 140-147, Chapter 13.
2. Frederick R.T. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol 2011, 7(4):222-233.
3. Ferenci P., Lockwood A., Mullen K., et al. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna 1998. Hepatology 2002, 35:716-721.
4. Poordad F.F. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):3-9.
5. Romero-Gomez M., Boza F., Garcia-Valdecasas M.S., et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001, 96:2718-2723.
6. Boyer T.D., Haskal Z.J. American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005, 41:386-400.
7. Bajaj J.S., Heuman D.M., Wade J.B., et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011, 140:478-487.
8. Riordan S.M., Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med 2010, 362(12):1140-1141.
9. Leevy C.B., Phillips J.A. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007, 52:737-741.
10. Bajaj J.S., Wade J.B., Gibson D.P., et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011, 106:1646-1653.
11. Higginson I.J., Gao W., Jackson D., et al. Short-form Zarit caregiver burden interviews were valid in advanced conditions. J Clin Epidemiol 2010, 63:535-542.
12. Bustamante J., Rimola A., Ventura P.J., et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999, 30:890-895.
13. Stewart C.A., Malinchoc M., Kim W.R., et al. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl 2007, 13:1366-1371.
14. Bajaj J.S., Schubert C.M., Sanyal A.J., et al. Severity of chronic cognitive impairment in cirrhosis increases with number of episodes of overt hepatic encephalopathy. J Hepatol 2010, 52(Suppl 1):S66.
15. Bajaj J.S., Schubert C.M., Heuman D.M., et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010, 138(7):2332-2340.
16. Fichet J., Mercier E., Genee O., et al. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care 2009, 24:364-370.
17. Phear E.A., Sherlock S. Summer skill WH. Blood-ammonium levels in liver disease and hepatic coma. Lancet 1955, 268:836-840.
18. Conn H.O., Lieberthal M.M. The hepatic coma syndromes and lactulose 1979, Williams & Wilkins, Baltimore (MD).
19. Olde Damink S.W., Jalan R., Redhead D.N., et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002, 36:1163-1171.
20. Romero-Gomez M., Ramos-Guerrero R., Grande L., et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004, 41:49-54.
21. Haussinger D., Sies H., Gerok W. Functional hepatocyte heterogeneity in ammonia metabolism. The intercellular glutamine cycle. J Hepatol 1985, 1:3-14.
22. Vinay P., Kemieux G., Gougoux A., et al. Regulation of glutamine metabolism in dog kidney in vivo. Kidney Int 1986, 29:68-79.
23. Tizianello A., Deferrari G., Garibotto G., et al. Renal ammoniagenesis in an early stage of metabolic acidosis in man. J Clin Invest 1982, 69:240-250.
24. Tizianello A., Deferrari G., Garibotto G., et al. Renal ammoniagenesis during the adaptation to metabolic acidosis in man. Contrib Nephrol 1988, 63:105-113.
25. Olde Damink S.W., Jalan R., Deutz N.E., et al. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 2003, 37:1277-1285.
26. Donovan J.P., Schafer D.F., Shaw B.W., et al. Cerebral edema and increased intracranial pressure in chronic liver disease. Lancet 1998, 351:719-721.
27. Kavitt R.T., Yang V.L., Jensen D.M. Cerebral edema and hyperammonemia after transjugular intrahepatic portosystemic shunt placement in a cirrhotic patient. Clin Gastroenterol Hepatol 2008, 6:1054-1056.
28. Norenberg M.D., Itzhak Y., Bender A.S. The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. Adv Exp Med Biol 1997, 420:95-111.
29. Mullen K.D., Szauter K.M., Kaminsky-Russ K. " Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990, 336:81-83.
30. Garcia-Ayllon M.S., Cauli O., Silveyra M.X., et al. Brain cholinergic impairment in liver failure. Brain 2008, 131:2946-2956.
31. Mendez M., Mendez-Lopez M., Lopez L., et al. Acetylcholinesterase activity in an experimental rat model of type C hepatic encephalopathy. Acta Histochem 2011, 113:358-362.
32. Basu P., Shah N.J., Krishnaswamy N., et al. Transdermal rivastigmine for treatment of encephalopathy in liver cirrhosis - a randomized placebo controlled trial (TREC TRIAL). J Hepatol 2010, 52(Suppl 1):S67-S68.
33. Guevara M., Baccaro M.E., Torre A., et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009, 104:1382-1389.
34. Angeli P., Wong F., Watson H., et al. CAPPS investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006, 44:1535-1542.
35. Vaquero J., Chung C., Blei A.T. Brain edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. Ann Hepatol 2003, 2:12-22.
36. Blei A.T. Infection, inflammation, and hepatic encephalopathy, synergism redefined. J Hepatol 2004, 40:327-330.
37. Pedersen H.R., Ring-Larsen H., Olsen N.V., et al. Hyperammonemia acts synergistically with lipopolysaccharide in inducing changes in cerebral hemodynamics in rats anaesthetized with pentobarbital. J Hepatol 2007, 47:245-252.
38. Perez del Pulgar S., Pizcueta P., Engel P., et al. Enhanced monocyte activation and hepatotoxicity in response to endotoxin in portal hypertension. J Hepatol 2000, 32:25-31.
39. Lumsden A.B., Henderson J.M., Kutner M.H. Endotoxin levels measured by a chromogenic assay in portal, hepatic, and peripheral blood in patients with cirrhosis. Hepatology 1988, 8:232-236.
40. Kalambokis G.N., Tsianos E.V. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 2012, 55:655-656.
41. Tilg H., Wilmer A., Vogel W., et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992, 103:264-274.
42. Garcia-Tsao G. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18:353-372.
43. Kalambokis G., Tsianos E.V. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could simple antibiotics raise blood counts?. Med Hypotheses 2011, 76:105-109.
44. Kalambokis G.N., Mouzaki A., Rodi M., et al. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int 2012, 32:467-475.
45. McGrath K.M., Stuart J.J., Richards F. Correlation between serum IgG, platelet membrane IgG, and platelet function in hypergammaglobulinemic states. Br J Haematol 1979, 42:585-591.
46. Kajihara M., Jato S., Okazaki Y., et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003, 37:1267-1276.
47. Violi F., Ferri D., Basili S., et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995, 109:531-539.
48. Schwager I., Jungi T.W. Effect of human recombinant cytokines on the induction of macrophages procoagulant activity. Blood 1994, 83:152-160.
49. Cordoba J., Blei A.T. Hepatic encephalopathy. Schiff's diseases of the liver 2007, vol. 1:569-599. Lippincott Williams & Wilkins, Philadelphia. 10th edition.
50. Hassanein T., Blei A.T., Perry W., et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol 2009, 104:1392-1400.
51. Williams R., James O.F., Morgan M.Y. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000, 12:203-208.
52. Conn H.O., Leevy C.M., Vlahcevic Z.R., et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic-encephalopathy: a double blind controlled trial. Gastroenterology 1977, 72:573-583.
53. Weissenborn K., Ennen J.C., Schomerus H., et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001, 34:768-773.
54. Schomerus H., Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001, 16:37-41.
55. Stewart C.A., Smith G.E. Minimal hepatic encephalopathy. Nat Clin Pract Gastroenterol Hepatol 2007, 4(12):677-685.
56. McCrea M., Cordoba J., Vessey M., et al. Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol 1996, 53(8):758-763.
57. Weissenborn K., Scholz M., Hinrichs H., et al. Neurophysiological characterization of hepatic encephalopathy. J Hepatol 2001, 34:768-773.
58. Quero J.C., Schalm S.W. Subclinical hepatic encephalopathy. Semin Liver Dis 1996, 16:321-328.
59. Kamath P.S. The need for better clinical trials. Hepatology 2008, 48:1-3.
60. Bajaj J.S., Etemadian A., Hafeezullah M., et al. Testing for minimal hepatic encephalopathy in the United States: an AASLD survey. Hepatology 2007, 45:833-834.
61. Blei A.T., Cordoba J., Practice Parameters Committee of the American College of Gastroenterology Hepatic encephalopathy. Am J Gastroenterol 2001, 96:1968-1976.
62. Riordan S.M., Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997, 337(7):473-479.
63. Munoz S.J. Hepatic encephalopathy. Med Clin North Am 2008, 92:795-812.
64. 4 levels and protein restriction obsolete?. Pract Gastroenterol 2011, 95:6-18.
65. Morgan M.Y., Blei A., Grungreiff K., et al. The treatment of hepatic encephalopathy. Metab Brain Dis 2007, 22:389-405.
66. Als-Nielsen B., Gluud L.L., Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 2004, 328:1046.
67. Sotil E.U., Gottstein J., Ayala E., et al. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 2009, 15:184-192.
68. Bass N.M. Review article the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):23-31.
69. Watanabe A., Sakai T., Sato S. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997, 26:1410-1414.
70. Sidhu S.S., Goyal O., Mishra B.P., et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (The RIME Trial). Am J Gastroenterol 2011, 106(2):307-316.
71. Mcphail M.J., Leech R., Grover V.P., et al. Functional core modulation following treatment of minimal hepatic encephalopathy with l-ornithine l-aspartate: a potential novel mechanism of action. 46th annual meeting of the european-association-for-the-study-of-the-liver (EASL) 2011, 54:S74-S75.
72. Devrajani B.R., Shah S.Z., Devrajani T., et al. Precipitating factors of hepatic encephalopathy at a tertiary care hospital Jamshoro, Hyderabad. J Pak Med Assoc 2009, 59:683-686.
73. Strauss E., Gomes de Sa Ribeiro Mde F. Bacterial infections associated with hepatic encephalopathy: prevalence and outcome. Ann Hepatol 2003, 2:41-45.
74. Zushi S., Imai Y., Fukuda K., et al. Endoscopic coagulation therapy is successful for improving encephalopathy in cirrhotic patients with gastric antral vascular ectasia. Dig Endosc 2005, 17:32-35.
75. Jalan R., Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut 2003, 52:1041-1045.
76. Pockros P., Hassanein T., Vierling J., et al. Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. lactulose in the treatment of low-grade hepatic encephalopathy. J Hepatol 2009, 50(Supp 1):S43-S44.
77. Kramer L., Tribl B., Gendo A., et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000, 31:30-34.
78. Ong J.P., Aggarwal A., Krieger D., et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003, 114:188-193.
79. Plauth M., Roske A.E., Romaniuk P., et al. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration. Gut 2000, 46:849-855.
80. Weissenborn K., Tietge U.J., Bokemeyer M., et al. Liver transplantation improves hepatic myelopathy: evidence by three cases. Gastroenterology 2003, 124:346-351.
81. Als-Nielsen B., Gluud L.L., Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004, 2. CD003044.
82. Sharma B.C., Sharma P., Agrawal A., et al. Secondary prophylaxis of hepatic encephalopathy: an open label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009, 137:885-891.
83. Lukers B., Nierman D.M., Schiano T.D. Lactulose: how many ways can one drug be prescribed?. Am J Gastroenterol 2011, 106(9):1726-1727.
84. Bass N. Treatment of patients with hepatic encephalopathy: review of the latest data from EASL 2011. Gastroenterol Hepatol 2011, 7(Suppl 9):1-15.
85. Malaguarnera M., Gargante M.P., Malaguarnera G., et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010, 22:199-206.
86. Iwasa M., Nakao M., Kato Y., et al. Dietary fiber decreases ammonia levels in patients with cirrhosis. Hepatology 2005, 41:217-218. [author reply: 219].
87. Liu Q., Duan Z.P., Ha D.K., et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
88. Seyan A.S., Hughes R.D., Shawcross D.L. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol 2010, 16:3347-3357.
89. Gentile S., Guarino G., Romano M., et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005, 3:184-191.
90. Gerard L., Garey K.W., DuPont H.L. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005, 3:201-211.
91. Jiang Z.D., DuPont H.L. Rifaximin: in vitro and in vivo antibacterial activity - a review. Chemotherapy 2005, 51(Suppl 1):67-72.
92. Debbia E.A., Maioli E., Roveta S., et al. Effects of rifaximin on bacterial virulence mechanisms at supra-and sub-inhibitory concentrations. J Chemother 2008, 20:186-194.
93. Sanyal A., Younossi Z.M., Bass N.M., et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011, 34:853-861.
94. Sanyal A., Bass N., Mullen K., et al. Rifaximin treatment improved quality of life in patients with hepatic encephalopathy: results of a large, randomized, placebo-controlled trial. J Hepatol 2010, 52(Suppl 1):S7.
95. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
96. Mullen K.D., Poordad F., Rossaro L., et al. Long term efficacy and survival in patients treated with the gut-selective antibiotic rifaximin (550 mg BID) for the maintenance of remission from overt hepatic encephalopathy. Gastroenterol Hepatol 2011, 7(6 Suppl 9):1-15.
97. Vlachogiannakos K., Viazis N., Vasianopoulou P., et al. Long-term administration of rifaximin improves the prognosis of patients with alcohol-related decompensated cirrhosis: a case-control study. Hepatology 2010, 52:328A.
98. Leise M.D., Pedersen R., Kamath P.S., et al. Impact of rifaximin treatment on survival in patients with end-stage liver disease. Hepatology 2010, 52:331A.
99. Jiang Q., Jiang G., Welty T.E., et al. Naloxone in the management of hepatic encephalopathy. J Clin Pharm Ther 2010, 35:333-341.
100. Als-Nielsen B., Gluud L.L., Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev 2004, 2. CD002798.
101. Cordoba J., Lopez-Hellin J., Planas M., et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004, 41:38-43.
102. Bajaj J.S. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010, 31(5):537-547.
103. Balzola F., Sanna C., Ottobrelli A., et al. Chronic hepatic encephalopathy (HE) in patients with severe liver cirrhosis: efficacy of the wheat and milk protein free diet in the reduction of clinical episodes. Gastroenterol Hepatol 2011, 7(6 Suppl 9):1-15.
104. Takuma Y., Nouso K., Makino Y., et al. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther 2010, 32:1080-1090.
105. Jiang Q., Jiang X.H., Zheng M.H., et al. L-ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2009, 24:9-14.
106. Ocera therapeutics completes first in human studies with OCR-002 for the treatment of hyperammonemia and hepatic encephalopathy 2010, Ocera, San Diego, CA.
107. Als-Nielsen B., Koretz R.L., Kjaergard L., et al. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003, 2. CD001939.
108. Malaguarnera M., Vacante M., Motta M., et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 2011, 26:281-289.
109. Hassanein T.I., Tofteng F., Brown R.S., et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007, 46:1853-1862.
110. Riggio O., Masini A., Efrati C., et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005, 42(5):674-679.
111. Kanematsu T., Koyanagi N., Matsumata T., et al. Lack of preventive effect of branched-chain amino acid solution on postoperative hepatic encephalopathy in patients with cirrhosis: a randomized, prospective trial. Surgery 1988, 104(3):482-488.
112. Rolachon A., Zarski J.P., Lutz J.M., et al. Is the intestinal lavage with a solution of mannitol effective in the prevention of post-hemorrhagic hepatic encephalopathy in patients with liver cirrhosis? Results of a randomized prospective study. Gastroenterol Clin Biol 1994, 18(12):1057-1062.
113. Uribe M., Campollo O., Vargas F., et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987, 7(4):639-643.
114. Kircheis G., Nilius R., Held C., et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997, 25(6):1351-1360.
115. Stauch S., Kircheis G., Adler G., et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998, 28(5):856-864.
116. Sushma S., Dasarathy S., Tandon R.K., et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992, 16(1):138-144.
117. Reding P., Duchateau J., Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 1984, 2(8401):493-495.
118. Riggio O., Ariosto F., Merli M., et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991, 36(9):1204-1208.